{"id":3415,"date":"2020-07-22T09:53:47","date_gmt":"2020-07-22T08:53:47","guid":{"rendered":"http:\/\/www.scottishmesotheliomanetwork.scot.nhs.uk\/?page_id=3415"},"modified":"2024-06-03T15:26:39","modified_gmt":"2024-06-03T14:26:39","slug":"quality-performance-indicators","status":"publish","type":"page","link":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/professionals\/quality-performance-indicators\/","title":{"rendered":"Quality Performance Indicators"},"content":{"rendered":"\n<p>The QPIs have been developed collaboratively with the three Regional Cancer Networks\u00a0 (<a href=\"http:\/\/www.scan.scot.nhs.uk\/\">SCAN<\/a>,\u00a0<a href=\"http:\/\/www.woscan.scot.nhs.uk\/\">WOSCAN<\/a>), Public Health Scotland, and Healthcare Improvement Scotland.\u00a0 The aim is to improve survival and patient experience whilst reducing variance and ensuring safe, effective and person-centred cancer care.\u00a0 The Quality Performance Indicators (QPIs) for mesothelioma are new and this is the first time Mesothelioma has been audited separately in Scotland.<\/p>\n\n\n\n<p><strong>Analysis of these QPIs is essential in improving and driving continuous improvement in Mesothelioma care<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 1 \u2013&nbsp; Diagnostic Imaging&nbsp;<\/h2>\n\n\n\n<p>(i) Proportion of patients in whom CT scan optimised for pleural assessment (between 60 and 90 seconds) is carried out for first discussion at the National MDT<\/p>\n\n\n\n<p>(ii) Proportion of patients in whom CT scan optimised for pleural assessment (between 60 and 90 seconds) is carried out for first discussion at the National MDT and TNM stage is recorded<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 2 \u2013&nbsp; Diagnostic Histopathology<\/h2>\n\n\n\n<p>(i) Proportion of patients with mesothelioma who have a histopathological diagnosis<\/p>\n\n\n\n<p>(ii) Proportion of patients with a histopathological diagnosis of mesothelioma who have a subtype identified<\/p>\n\n\n\n<p>(iii) Proportion of patients with a histopathological diagnosis of epthelioid who have IHC marks profiling undertaken<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 3 \u2013 Multidisciplinary Team&nbsp;<\/h2>\n\n\n\n<p>Proportion of patients with mesothelioma who are discussed at the national mesothelioma MDT meeting<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 4 \u2013 Systemtic Anti Cancer Treatment&nbsp;<\/h2>\n\n\n\n<p>Proportion of patients with mesothelioma and performance status (PS) 0-1 who receive first line treatment with SACT using Platinum and Pemetrexed<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 5 \u2013 Radiotherapy for Management of Pain<\/h2>\n\n\n\n<p>Proportion of patients with mesothelioma who are referred to the national MDT for pain relief who receive radiotherapy<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 6 \u2013 Pleural Fluid Management&nbsp;<\/h2>\n\n\n\n<p>Proportion of patients with mesothelioma with symptomatic pleural effusion who undergo either talc pleurodesis or indwelling pleural catheter (IPC) insertion to manage fluid<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 7 \u2013 Clinical Trial and Research Study Access&nbsp;<\/h2>\n\n\n\n<p>Proportion of patients with mesothelioma who are consented for a clinical trial\/research study<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">QPI 8 \u2013 Post Mortem Examination<\/h2>\n\n\n\n<p>Proportion of patients who have died with a pathological diagnosis of mesothelioma who undergo post-mortem examination<\/p>\n\n\n\n<p>Please&nbsp;<a href=\"https:\/\/www.scottishmesotheliomanetwork.scot.nhs.uk\/mesothelioma-qpi-reports\/\">here<\/a>&nbsp;click to view our current QPI report and to access previous reports.<\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"nhsuk-card__description\">The QPIs have been developed collaboratively with the three Regional Cancer Networks\u00a0 (SCAN,\u00a0WOSCAN), Public Health Scotland, and Healthcare Improvement Scotland.\u00a0 [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"parent":2862,"menu_order":4,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3415","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/pages\/3415","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/comments?post=3415"}],"version-history":[{"count":26,"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/pages\/3415\/revisions"}],"predecessor-version":[{"id":6479,"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/pages\/3415\/revisions\/6479"}],"up":[{"embeddable":true,"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/pages\/2862"}],"wp:attachment":[{"href":"https:\/\/www.nn.nhs.scot\/scottishmesotheliomanetwork\/wp-json\/wp\/v2\/media?parent=3415"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}